Abdeslam Chagraoui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3772159/publications.pdf

Version: 2024-02-01

49 papers

1,547 citations

³⁹⁴⁴²¹ 19 h-index 39 g-index

52 all docs 52 docs citations

times ranked

52

1766 citing authors

#	Article	IF	CITATIONS
1	Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson's Disease. Biomolecules, 2022, 12, 243.	4.0	4
2	Cannabinoid $1/2$ Receptor Activation Induces Strain-Dependent Behavioral and Neurochemical Changes in Genetic Absence Epilepsy Rats From Strasbourg and Non-epileptic Control Rats. Frontiers in Cellular Neuroscience, 2022, 16, .	3.7	3
3	Serotonin modulation of hippocampal functions: From anatomy to neurotherapeutics. Progress in Brain Research, 2021, 261, 83-158.	1.4	20
4	Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence. Progress in Brain Research, 2021, 261, 161-264.	1.4	11
5	Cell-penetrating, antioxidant SELENOT mimetic protects dopaminergic neurons and ameliorates motor dysfunction in Parkinson's disease animal models. Redox Biology, 2021, 40, 101839.	9.0	20
6	Dopamine D3 Receptor: Contemporary Views of Its Function and Pharmacology for Neuropsychiatric Diseases. Biomolecules, $2021, 11, 713$.	4.0	O
7	L-DOPA in Parkinson's Disease: Looking at the "False―Neurotransmitters and Their Meaning. International Journal of Molecular Sciences, 2020, 21, 294.	4.1	60
8	Lorcaserin bidirectionally regulates dopaminergic function site-dependently and disrupts dopamine brain area correlations in rats. Neuropharmacology, 2020, 166, 107915.	4.1	24
9	A Subset of Purposeless Oral Movements Triggered by Dopaminergic Agonists Is Modulated by 5-HT2C Receptors in Rats: Implication of the Subthalamic Nucleus. International Journal of Molecular Sciences, 2020, 21, 8509.	4.1	5
10	Chronic Administration of Fipronil Heterogeneously Alters the Neurochemistry of Monoaminergic Systems in the Rat Brain. International Journal of Molecular Sciences, 2020, 21, 5711.	4.1	12
11	Editorial: Contemporary Perspective on 5-HT2C Receptor Function and Its Pharmacological Targeting. Frontiers in Pharmacology, 2020, 11, 606414.	3.5	4
12	Lorcaserin Alters Serotonin and Noradrenaline Tissue Content and Their Interaction With Dopamine in the Rat Brain. Frontiers in Pharmacology, 2020, 11, 962.	3.5	9
13	Epigenetics and Attention-Deficit/Hyperactivity Disorder: New Perspectives?. Frontiers in Psychiatry, 2020, 11, 579.	2.6	10
14	Constitutive activity of 5-HT receptors: Factual analysis. Neuropharmacology, 2020, 168, 107967.	4.1	41
15	Serotonergic control of excitability: from neuron to networks. Handbook of Behavioral Neuroscience, 2020, 31, 197-215.	0.7	3
16	Coronaridine congeners potentiate GABAA receptors and induce sedative activity in mice in a benzodiazepine-insensitive manner. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 101, 109930.	4.8	7
17	Motivation and motivational aspects of Parkinson's disease. , 2020, , 497-509.		O
18	Reciprocal interaction between monoaminergic systems and the pedunculopontine nucleus: Implication in the mechanism of L-DOPA. Neurobiology of Disease, 2019, 128, 9-18.	4.4	6

#	Article	IF	CITATIONS
19	Effect of the 5-HT2C Receptor Agonist WAY-163909 on Serotonin and Dopamine Metabolism across the Rat Brain: A Quantitative and Qualitative Neurochemical Study. International Journal of Molecular Sciences, 2019, 20, 2925.	4.1	12
20	Early neurochemical modifications of monoaminergic systems in the R6/1 mouse model of Huntington's disease. Neurochemistry International, 2019, 128, 186-195.	3.8	19
21	Neurochemical impact of the 5-HT2C receptor agonist WAY-163909 on monoamine tissue content in the rat brain. Neurochemistry International, 2019, 124, 245-255.	3.8	21
22	WFSBP and IAWMH Guidelines for the treatment of alcohol use disorders in pregnant women. World Journal of Biological Psychiatry, 2019, 20, 17-50.	2.6	31
23	The pathophysiological mechanisms of motivational deficits in Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 138-152.	4.8	10
24	La pharmacie orthopédique en milieu hospitalierÂ: une autre pratique de la pharmacie clinique. Pharmacien Hospitalier Et Clinicien, 2017, 52, 293-298.	0.3	0
25	Dipotassium ethylenediaminetetraacetic acid is better than tripotassium salt for electrochemiluminescence insulin measurement. Clinica Chimica Acta, 2016, 463, 45-46.	1.1	1
26	To what extent is it possible to dissociate the anxiolytic and sedative/hypnotic properties of GABAA receptors modulators?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 71, 189-202.	4.8	10
27	5-HT2C receptors in psychiatric disorders: A review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 66, 120-135.	4.8	87
28	Selenoprotein T Exerts an Essential Oxidoreductase Activity That Protects Dopaminergic Neurons in Mouse Models of Parkinson's Disease. Antioxidants and Redox Signaling, 2016, 24, 557-574.	5.4	91
29	Selenoprotein T: From Discovery to Functional Studies Using Conditional Knockout Mice. , 2016, , 275-286.		3
30	Haemoglobin J-Baltimore can be detected by HbA1c electropherogram but with underestimated HbA1c value. Biochemia Medica, 2016, 26, 240-242.	2.7	2
31	Fortuitous detection of a case of unknown haemoglobin Athens-Georgia from atypical HbA1c electropherogram. Clinica Chimica Acta, 2015, 440, 6-7.	1.1	3
32	The PACAP-Regulated Gene Selenoprotein T Is Highly Induced in Nervous, Endocrine, and Metabolic Tissues during Ontogenetic and Regenerative Processes. Endocrinology, 2011, 152, 4322-4335.	2.8	50
33	Structure–affinity relationships of halogenated predicentrine and glaucine derivatives at D1 and D2 dopaminergic receptors: halogenation and D1 receptor selectivity. Bioorganic and Medicinal Chemistry, 2005, 13, 3699-3704.	3.0	34
34	Long-Term Heart Rate Reduction Induced by the Selective <i>I</i> _f Current Inhibitor Ivabradine Improves Left Ventricular Function and Intrinsic Myocardial Structure in Congestive Heart Failure. Circulation, 2004, 109, 1674-1679.	1.6	281
35	Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT 2C receptors in Wistar rats. Psychopharmacology, 2003, 170, 17-22.	3.1	53
36	Effects of some antioxidative aporphine derivatives on striatal dopaminergic transmission and on MPTP-induced striatal dopamine depletion in B6CBA mice. European Journal of Pharmaceutical Sciences, 2003, 18, 133-140.	4.0	17

#	Article	IF	CITATIONS
37	Tissue Doppler Imaging Differentiates Physiological From Pathological Pressure-Overload Left Ventricular Hypertrophy in Rats. Circulation, 2002, 105, 1602-1608.	1.6	137
38	Syntheses of dopaminergic 1-cyclohexylmethyl-7,8-dioxygenated tetrahydroisoquinolines by selective heterogeneous tandem hydrogenation. Tetrahedron, 2002, 58, 10173-10179.	1.9	14
39	Enantioselective Syntheses of Dopaminergic (R)- and (S)-Benzyltetrahydroisoquinolines. Journal of Medicinal Chemistry, 2001, 44, 1794-1801.	6.4	44
40	Preparation of dopaminergic N -alkyl-benzyltetrahydro-isoquinolines using a â€~one-pot' procedure in acid medium. Bioorganic and Medicinal Chemistry, 2000, 8, 889-895.	3.0	19
41	New investigations within the TeO2-WO3 system: phase equilibrium diagram and glass crystallization. Journal of Materials Science, 1999, 34, 4285-4292.	3.7	90
42	Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents. European Journal of Pharmacology, 1994, 271, 167-177.	3.5	36
43	Effects of chronic treatments with amineptine and despiramine on motor responses involving dopaminergic systems. Psychopharmacology, 1990, 102, 201-206.	3.1	15
44	The rise of body temperature induced by the stimulation of dopamine D1 receptors is increased in acutely reserpinized mice. European Journal of Pharmacology, 1990, 181, 23-33.	3.5	11
45	Interaction of Amineptine with Agents Modifying Dopaminergic Transmission. Clinical Neuropharmacology, 1989, 12, S19-S31.	0.7	4
46	Climbing and stereotyped behaviours in mice require the stimulation of D-1 dopamine receptors. European Journal of Pharmacology, 1988, 148, 221-229.	3.5	47
47	In vivo binding of [3H]GBR 12783, a selective dopamine uptake inhibitor, in mouse striatum. Neuroscience Letters, 1987, 78, 175-179.	2.1	30
48	Interactions of amineptine with the neuronal dopamine uptake system: Neurochemicalin vitro andin vivo studies. Journal of Neural Transmission, 1987, 69, 211-220.	2.8	28
49	High-affinity [3H]GBR 12783 binding to a specific site associated with the neuronal dopamine uptake complex in the central nervous system. European Journal of Pharmacology, 1986, 126, 211-222.	3.5	108